| Basics |
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
|
| IPO Date: |
May 11, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.35B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.22 | 2.61%
|
| Avg Daily Range (30 D): |
$0.43 | 2.88%
|
| Avg Daily Range (90 D): |
$0.67 | 3.50%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.74M |
| Avg Daily Volume (30 D): |
1.55M |
| Avg Daily Volume (90 D): |
1.68M |
| Trade Size |
| Avg Trade Size (Sh.): |
79 |
| Avg Trade Size (Sh.) (30 D): |
84 |
| Avg Trade Size (Sh.) (90 D): |
81 |
| Institutional Trades |
| Total Inst.Trades: |
5,250 |
| Avg Inst. Trade: |
$3.1M |
| Avg Inst. Trade (30 D): |
$2.29M |
| Avg Inst. Trade (90 D): |
$2.28M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.97M |
| Avg Closing Trade (30 D): |
$3.01M |
| Avg Closing Trade (90 D): |
$3.6M |
| Avg Closing Volume: |
105.67K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-2.17
|
$-1.7
|
|
Diluted EPS
|
|
$-2.17
|
$-1.7
|
|
Revenue
|
$
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -221.68M
|
$ -160.3M
|
|
Operating Income / Loss
|
$
|
$ -221.56M
|
$ -178.17M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ .15M
|
$ -154.3M
|
|
PE Ratio
|
|
|
|
|
|
|
